These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 35319491)

  • 1. Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement.
    Boguszewski MCS; Boguszewski CL; Chemaitilly W; Cohen LE; Gebauer J; Higham C; Hoffman AR; Polak M; Yuen KCJ; Alos N; Antal Z; Bidlingmaier M; Biller BMK; Brabant G; Choong CSY; Cianfarani S; Clayton PE; Coutant R; Cardoso-Demartini AA; Fernandez A; Grimberg A; Guðmundsson K; Guevara-Aguirre J; Ho KKY; Horikawa R; Isidori AM; Jørgensen JOL; Kamenicky P; Karavitaki N; Kopchick JJ; Lodish M; Luo X; McCormack AI; Meacham L; Melmed S; Mostoufi Moab S; Müller HL; Neggers SJCMM; Aguiar Oliveira MH; Ozono K; Pennisi PA; Popovic V; Radovick S; Savendahl L; Touraine P; van Santen HM; Johannsson G
    Eur J Endocrinol; 2022 Apr; 186(6):P35-P52. PubMed ID: 35319491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of growth hormone (GH) treatment in GH deficient children and adults treated for cancer and non-malignant intracranial tumors-a review of research and clinical practice.
    Boguszewski MCS; Cardoso-Demartini AA; Boguszewski CL; Chemaitilly W; Higham CE; Johannsson G; Yuen KCJ
    Pituitary; 2021 Oct; 24(5):810-827. PubMed ID: 34304361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer risk following growth hormone use in childhood: implications for current practice.
    Ogilvy-Stuart AL; Gleeson H
    Drug Saf; 2004; 27(6):369-82. PubMed ID: 15144231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does GH replacement therapy in adult GH-deficient patients result in recurrence or increase in size of pituitary tumours?
    Hatrick AG; Boghalo P; Bingham JB; Ayres AB; Sonksen PH; Russell-Jones DL
    Eur J Endocrinol; 2002 Jun; 146(6):807-11. PubMed ID: 12039701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia.
    Ho KK;
    Eur J Endocrinol; 2007 Dec; 157(6):695-700. PubMed ID: 18057375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour surveillance imaging in patients with extrapituitary tumours receiving growth hormone replacement.
    Chung TT; Drake WM; Evanson J; Walker D; Plowman PN; Chew SL; Grossman AB; Besser GM; Monson JP
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):274-9. PubMed ID: 16117814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety of growth hormone replacement therapy in survivors of cancer and tumors of the pituitary region.
    Bolier M; van der Lelij AJ; Janssens GO; van den Heuvel-Eibrink MM; Neggers SJCMM
    Endocr Relat Cancer; 2023 Jul; 30(7):. PubMed ID: 37043373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS AND PATIENTS TRANSITIONING FROM PEDIATRIC TO ADULT CARE.
    Yuen KCJ; Biller BMK; Radovick S; Carmichael JD; Jasim S; Pantalone KM; Hoffman AR
    Endocr Pract; 2019 Nov; 25(11):1191-1232. PubMed ID: 31760824
    [No Abstract]   [Full Text] [Related]  

  • 9. Does growth hormone cause cancer?
    Jenkins PJ; Mukherjee A; Shalet SM
    Clin Endocrinol (Oxf); 2006 Feb; 64(2):115-21. PubMed ID: 16430706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of pituitary tumours: impact of GH secretory status and long-term GH replacement therapy.
    Gasco V; Caputo M; Cambria V; Beccuti G; Caprino MP; Ghigo E; Maccario M; Grottoli S
    Endocrine; 2019 Feb; 63(2):341-347. PubMed ID: 30341707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety.
    Abs R; Bengtsson BA; Hernberg-Stâhl E; Monson JP; Tauber JP; Wilton P; Wüster C
    Clin Endocrinol (Oxf); 1999 Jun; 50(6):703-13. PubMed ID: 10468941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of primary cancers and intracranial tumour recurrences in GH-treated and untreated adult hypopituitary patients: analyses from the Hypopituitary Control and Complications Study.
    Child CJ; Conroy D; Zimmermann AG; Woodmansee WW; Erfurth EM; Robison LL
    Eur J Endocrinol; 2015 Jun; 172(6):779-90. PubMed ID: 25810462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GH and Childhood-onset Craniopharyngioma: When to Initiate GH Replacement Therapy?
    Nguyen Quoc A; Beccaria K; González Briceño L; Pinto G; Samara-Boustani D; Stoupa A; Beltrand J; Besançon A; Thalassinos C; Puget S; Blauwblomme T; Alapetite C; Bolle S; Doz F; Grill J; Dufour C; Bourdeaut F; Abbou S; Guerrini-Rousseau L; Leruste A; Brabant S; Cavadias I; Viaud M; Boddaert N; Polak M; Kariyawasam D
    J Clin Endocrinol Metab; 2023 Jul; 108(8):1929-1936. PubMed ID: 36794424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The characteristics of quality of life impairment in adult growth hormone (GH)-deficient survivors of cancer and their response to GH replacement therapy.
    Mukherjee A; Tolhurst-Cleaver S; Ryder WD; Smethurst L; Shalet SM
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1542-9. PubMed ID: 15613427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controversies in the risk of neoplasia in GH deficiency.
    Pekic S; Stojanovic M; Popovic V
    Best Pract Res Clin Endocrinol Metab; 2017 Feb; 31(1):35-47. PubMed ID: 28477731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of Growth Hormone Replacement Therapy in Childhood-Onset Craniopharyngioma: A Systematic Review and Cohort Study.
    van Schaik J; Kormelink E; Kabak E; van Dalen EC; Schouten-van Meeteren AYN; de Vos-Kerkhof E; Bakker B; Fiocco M; Hoving EW; Tissing WJE; van Santen HM
    Neuroendocrinology; 2023; 113(10):987-1007. PubMed ID: 37231961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of growth hormone treatment in children with craniopharyngioma with reference to the KIGS (Kabi International Growth Study) database.
    Price DA; Jönsson P
    Acta Paediatr Suppl; 1996 Oct; 417():83-5. PubMed ID: 9055921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults.
    Allen DB; Backeljauw P; Bidlingmaier M; Biller BM; Boguszewski M; Burman P; Butler G; Chihara K; Christiansen J; Cianfarani S; Clayton P; Clemmons D; Cohen P; Darendeliler F; Deal C; Dunger D; Erfurth EM; Fuqua JS; Grimberg A; Haymond M; Higham C; Ho K; Hoffman AR; Hokken-Koelega A; Johannsson G; Juul A; Kopchick J; Lee P; Pollak M; Radovick S; Robison L; Rosenfeld R; Ross RJ; Savendahl L; Saenger P; Sorensen HT; Stochholm K; Strasburger C; Swerdlow A; Thorner M
    Eur J Endocrinol; 2016 Feb; 174(2):P1-9. PubMed ID: 26563978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiological growth hormone replacement and rate of recurrence of craniopharyngioma: the Genentech National Cooperative Growth Study.
    Smith TR; Cote DJ; Jane JA; Laws ER
    J Neurosurg Pediatr; 2016 Oct; 18(4):408-412. PubMed ID: 27286443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of Neoplasia in Pediatric Patients Receiving Growth Hormone Therapy--A Report From the Pediatric Endocrine Society Drug and Therapeutics Committee.
    Raman S; Grimberg A; Waguespack SG; Miller BS; Sklar CA; Meacham LR; Patterson BC
    J Clin Endocrinol Metab; 2015 Jun; 100(6):2192-203. PubMed ID: 25839904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.